Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
about
Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early TreatmentPreexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative reviewHow Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores"A pill for HIV prevention: déjà vu all over again?Preexposure prophylaxis for HIV prevention: where have we been and where are we going?Preventing HIV infection: pre-exposure and postexposure prophylaxisPre-exposure prophylaxis for sexually-acquired HIV risk management: a reviewAntiretroviral pharmacology in mucosal tissuesDivergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyPatterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, GeorgiaAdherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East AfricaSafety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trialNo evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisStrong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menKnowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical SettingHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactAntiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA ReservoirsTowards preparedness for PrEP: PrEP awareness and acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, Wales, Northern Ireland and The Republic of Ireland: an online survey.Disclosure of pharmacokinetic drug results to understand nonadherenceSexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men.High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.The HIV-Brazil cohort study: design, methods and participant characteristics.Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, PeruImportance of Drug Pharmacokinetics at the Site of ActionPreexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.Optimal costs of HIV pre-exposure prophylaxis for men who have sex with menFEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.Biomedical prevention: state of the science.Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couplesPre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study)Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
P2860
Q26778085-71EC8339-DB7E-46D5-AD6F-75CDBEE0434DQ26778293-CB7BB941-DC8A-4167-8CCD-6D96E5E893A7Q26798250-D4C005AA-78C2-4CC3-AE9C-885455811E80Q26824606-3D054C9E-7BC5-4710-9523-34C1D369BDB5Q26825042-97249B03-F3D6-40DE-B874-CD3B04D4BA61Q26828445-E262D858-F0E8-44C5-B8C6-8EB1B2ABF3A3Q26849762-79124D62-8F4A-4711-8891-CF005D7160CCQ27014675-B63CB21F-9353-4885-83DD-C91D56230F17Q27300707-F29503C0-16B1-4255-BBBA-264AA57CE5CAQ27313352-10AF1C27-67E0-4E2E-8E8B-07B017E88A2CQ28088473-B7F00ACD-A67D-4E63-ADCA-D02327A96CBCQ28533158-8BF4269C-7928-4FF6-A93A-68A8CBC6B1F1Q28533828-811AEDC0-3F95-4A6C-89AC-3C7408520218Q28537713-1CCF3B6C-A15F-458F-981C-58DD7B2CE6E4Q28538457-9A595822-6B02-4775-9008-CD0834D6CB77Q28540969-6428BBAD-9653-43CB-963F-CC4673E19D9EQ28547765-3EE9D9D4-F487-447E-9482-B40DCC9B8501Q28552015-D604E728-48BA-435D-A0A1-EB2781CC38AFQ28552455-59A80169-9F71-4ADA-88C6-B3D0265BC239Q28553127-905E15B5-FBF0-448C-B3D1-49C79BEF2771Q30196896-CF856C6E-0276-4FCD-AB81-25FDB0766DDBQ30674432-71302814-74B3-4568-A683-D26C5C4D6334Q30698590-37E16C4C-6BC2-4DC9-B620-E30891755A59Q30877918-95F65162-EC80-4D6E-B6F4-DEA2CE9E4B37Q33553184-EAF878C5-B5DB-478B-93B9-AC912F2279E9Q33566562-E4A54317-0140-434E-8B17-79AAFF5F87C2Q33648045-297A1F26-751A-42B8-8267-EAFA41902B20Q33656112-F2F3E1A6-A58C-446E-B9E0-4DA1BFACA0FCQ33751621-E381EEAF-9D46-48F3-AF40-8A973A342D45Q33762990-1A4B086B-A956-4483-9F14-209367CA768EQ33763000-28E2C735-758D-4DEC-9EB1-7F42E8EFEFF8Q33765795-62E9AAAD-F419-4F40-87C7-003B7080B691Q33798045-70A8CAAC-D4AF-4ADB-8C29-1A2162678CD6Q33888718-5CD298F7-4C28-4708-AA80-0C1BABADC6BAQ33909720-07F805F3-413D-4B3D-B1D4-02C2FE4CE40CQ33948938-3E393146-C893-4AAB-B738-2EE1DDCA5370Q34021932-ACFACE68-25F0-4F94-9C39-974CA6E209D5Q34022009-58D4B850-933E-4015-B450-D1C1B31FB9B5Q34034418-29466070-B65E-42BC-B999-0DC3D84C200EQ34046430-9128237D-B991-4D19-BB07-627A785F125F
P2860
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@en
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@nl
type
label
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@en
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@nl
prefLabel
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@en
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@nl
P2093
P2860
P50
P1476
Emtricitabine-tenofovir concen ...... in men who have sex with men.
@en
P2093
Albert Liu
David V Glidden
Esper Georges Kallás
Javier R Lama
Lane R Bushman
Martín Casapía
Mauro Schechter
Orlando Montoya-Herrera
Peter L Anderson
Suwat Chariyalertsak
P2860
P304
P356
10.1126/SCITRANSLMED.3004006
P407
P577
2012-09-01T00:00:00Z